Kintor Pharmaceutical Ltd (HK:9939)
:9939
Want to see HK:9939 full AI Analyst Report?
Top Page
Kintor Pharmaceutical Ltd
(9939)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$3.00
▲(56.25% Upside)
Action:Reiterated
Date:05/03/26
The score is held back primarily by weak financial performance (ongoing losses, negative gross profit, and continued cash burn alongside a shrinking equity base). Technicals are mixed/neutral and do not strongly offset the financial risk, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Revenue rebound (2025)
A sharp revenue rebound in 2025 signals improving commercial or milestone traction versus prior years. Over a 2–6 month horizon this trend supports operational continuity, reduces near-term reliance on financing if sustained, and indicates improving demand or successful program monetization.
Negative Factors
Negative gross profit & losses
Persistently negative gross profit and operating losses indicate the core business is not yet generating unit-level economics sufficient to cover costs. This structural unprofitability erodes equity, limits reinvestment capacity, and implies reliance on external funding until margins sustainably improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound (2025)
A sharp revenue rebound in 2025 signals improving commercial or milestone traction versus prior years. Over a 2–6 month horizon this trend supports operational continuity, reduces near-term reliance on financing if sustained, and indicates improving demand or successful program monetization.
Read all positive factors
Kintor Pharmaceutical Ltd (9939) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.33B
Dividend YieldN/A
Average Volume (3M)4.99M
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth557.36%
EPS Growth-24.06%
CountryHK
Employees168
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.44
Shares Outstanding498,660,100
10 Day Avg. Volume2,605,850
30 Day Avg. Volume4,990,601
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.33
Price to Sales (P/S)24.23
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kintor Pharmaceutical Ltd Business Overview & Revenue Model
Company Description
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the P...
How the Company Makes Money
null...
Kintor Pharmaceutical Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 32.68M | 5.00M | 0.00 | 0.00 | 34.23M |
| Gross Profit | 8.04M | -4.73M | -67.63M | -21.38M | 34.23M |
| EBITDA | -140.66M | -128.37M | -1.06B | -956.45M | -829.09M |
| Net Income | -200.11M | -155.29M | -1.06B | -954.37M | -842.10M |
Balance Sheet | |||||
| Total Assets | 340.95M | 515.13M | 869.23M | 2.06B | 2.07B |
| Cash, Cash Equivalents and Short-Term Investments | 34.78M | 147.42M | 455.50M | 875.08M | 1.06B |
| Total Debt | 86.64M | 133.01M | 253.92M | 286.39M | 159.73M |
| Total Liabilities | 158.28M | 221.05M | 411.12M | 559.95M | 412.83M |
| Stockholders Equity | 182.67M | 294.08M | 458.11M | 1.50B | 1.66B |
Cash Flow | |||||
| Free Cash Flow | -166.07M | -200.76M | -390.30M | -988.73K | -1.13M |
| Operating Cash Flow | -165.34M | -199.08M | -387.58M | -961.26K | -1.05M |
| Investing Cash Flow | 14.04M | 20.03M | 3.27M | 67.19K | 92.00K |
| Financing Cash Flow | 39.23M | -119.67M | -33.46M | 815.75K | 857.42K |
Kintor Pharmaceutical Ltd Technical Analysis
Negative
1.92
Price Trends
3.00
Negative
2.75
Negative
2.46
Positive
Market Momentum
-0.04
Positive
42.06
Neutral
7.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9939, the sentiment is Negative. The current price of 1.92 is below the 20-day moving average (MA) of 2.84, below the 50-day MA of 3.00, and below the 200-day MA of 2.46, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 42.06 is Neutral, neither overbought nor oversold. The STOCH value of 7.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9939.
Kintor Pharmaceutical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.33B | -15.87 | -6.26% | ― | -11.65% | -169.40% | |
49 Neutral | HK$10.20B | -82.36 | -11.81% | ― | 219.26% | 87.63% | |
47 Neutral | HK$1.33B | -3.96 | -102.50% | ― | 557.36% | -24.06% | |
46 Neutral | HK$4.20B | -12.96 | -17.64% | ― | -65.87% | 6.71% | |
44 Neutral | HK$893.29M | -6.62 | -26.82% | ― | -20.21% | 2.98% | |
44 Neutral | HK$14.37B | -6.78 | -123.74% | ― | -41.32% | -159.81% |
* Healthcare Sector Average
HK:9939
Kintor Pharmaceutical Ltd
2.64
1.21
84.62%
HK:9966
Alphamab Oncology
8.80
-0.18
-2.00%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
5.30
0.49
10.19%
HK:1244
3D Medicines, Inc.
3.20
-0.57
-15.12%
HK:2171
CARsgen Therapeutics Holdings Ltd.
17.51
-5.19
-22.86%
HK:6855
Ascentage Pharma Group International
40.34
-8.41
-17.25%
Kintor Pharmaceutical Ltd Corporate Events
Kintor Pharmaceutical Surges in E‑commerce and B2B Sales to Fund Core Drug Pipeline
Apr 20, 2026
Kintor Pharmaceutical reported a sharp acceleration in both B2C and B2B sales since the start of 2026, with year‑to‑date revenue already reaching about RMB34 million and surpassing its full‑year 2025 total of RMB32.68 million. Th...
Kintor’s Cosmetics-Driven Revenue Soars but Loss Widens on Pipeline Shift
Mar 30, 2026
Kintor Pharmaceutical reported a surge in revenue to RMB32.7 million for 2025, up 554% year-on-year, driven mainly by global sales of its KOSHINÉ high-end cosmetics brand, where core compound KX-826 is a key ingredient and livestream e-commer...
Kintor Pharmaceutical Delays Board Meeting to Approve 2025 Annual Results
Mar 23, 2026
Kintor Pharmaceutical Limited has postponed its scheduled board meeting, originally set for March 26, 2026, to March 30, 2026, due to the directors’ timetable constraints. The meeting’s agenda includes reviewing and approving the compa...
Kintor’s KX-826 Hits Phase III Goal in China AGA Trial, NDA Planned
Mar 18, 2026
Kintor Pharmaceutical said its in-house developed topical drug KX-826 1.0% achieved the primary endpoint in the phase III stage of a pivotal clinical trial for male androgenetic alopecia in China, delivering statistically significant and clinicall...
Kintor Ties Up With Chicmax to Commercialize KT-939 Whitening Ingredient and Fund Core Drug Pipeline
Mar 17, 2026
Kintor Pharmaceutical’s subsidiary Suzhou Kintor has signed an exclusive strategic cooperation framework agreement with Shanghai Chicmax Cosmetic to rapidly commercialize KT-939, a whitening and freckle-removing functional cosmetic raw mater...
Kintor Partners With Fonow Medicine to Commercialize KT-939 Functional Cosmetics in China
Mar 12, 2026
Kintor Pharmaceutical’s subsidiary Suzhou Kintor has signed a strategic cooperation agreement with Zhejiang Fonow Medicine to jointly develop whitening and freckle-removing functional cosmetics using Kintor’s innovative raw material KT...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.